title: Shared scheme for assessing drugs for multiple sclerosis: why are eyes tightly shut to considering causes other than autoimmunity?
authors.forename: Abhijit
authors.initials: A
authors.lastname: Chaudhuri
authors.forename: Peter O
authors.initials: PO
authors.lastname: Behan
mesh_terms: D000276:Adjuvants, Immunologic / Q000191:economics*; D002986:Clinical Trials as Topic; D000068717:Glatiramer Acetate; D006801:Humans; D007166:Immunosuppressive Agents / Q000191:economics*; D016899:Interferon-beta / Q000191:economics*; D009103:Multiple Sclerosis / Q000188:drug therapy*; D010455:Peptides / Q000191:economics*
chemical_list: D000276:Adjuvants, Immunologic; D007166:Immunosuppressive Agents; D010455:Peptides; D000068717:Glatiramer Acetate; D016899:Interferon-beta